Speak to Analyst
Request a Free Sample
Cardiac Resynchronization Therapy Market Forecast
The Cardiac Resynchronization Therapy Market is anticipated to reach USD 4.09 Billion by 2030 at 4.10% CAGR during the forecast period 2022-2030.
Market Synopsis
The increasing prevalence rate of cardiac diseases followed by, rising demand for invasive techniques, fueling market growth. Cardiac disease is the leading cause of death for US population. In 2018, it was estimated that 2,300 people died in America per day due to cardiovascular diseases. Also, around 92.1 million American adult population are living with some form of cardiac disease or the aftereffects of the stroke.
Cardiac diseases are most common in low- and middle-income countries and these disorders.
Cardiac Resynchronization Therapy (CRT) Market Influencer
Increasing awareness of cardiac resynchronization therapy (CRT) devices and favorable government regulation towards reimbursement scenario.
Cardiac Resynchronization Therapy (CRT) Market Drivers
- Increasing sedentary lifestyle – leading a sedentary lifestyle is a major public health issue, it is increasingly spreading in many nations irrespective of being linked to various type of chronic health conditions.
- Rising geriatric population
- Rising investments in the healthcare sector – In 2016, the expenditure of US on medical and health research and development (R&D) was around USD 171.8 billion, and US healthcare expenditure was USD 3482.2 billion.
- Increasing technologically advances in medical devices
- The rising number of surgical procedures
- The growing number of intensive care units
Cardiac Resynchronization Therapy (CRT) Market Restraints
- The high cost of therapy – In 2017, the initial cost of cardiac resynchronization therapy pacemaker (CRT-P) is USD 16,218.44 and USD 36,263.73 of cardiac resynchronization therapy defibrillator (CRT-D).
Cardiac Resynchronization Therapy (CRT) Market Segmentation
By Application
- Intraventricular dyssynchrony: This segment holds the largest share because majority of the patients are estimated to be suffering from intraventricular dyssynchrony due to heart failure and left bundle branch block.
- Interventricular (V-V) dyssynchrony: This segment holds the second largest segment of the cardiac resynchronization therapy market. V-V dyssynchrony occurs when there is interruption or delay between the right ventricle and left ventricle activation.
- Atrioventricular (A-V) dyssynchrony: The A-V dyssynchrony occurs due to atrial and ventricle contraction, which can result in shortened ventricle filling time and mispositioning of atrial contraction.
By Type
- Cardiac resynchronization therapy pacemaker (CRT-P): This segment holds the highest cardiac resynchronization therapy market share. In 2019, a study showed patients using CRT-P had 33% of death rate out of 135 patients.
- Cardiac resynchronization therapy defibrillator (CRT-D): This segment is not as popular as CRT-D, the study shows patients using this therapy has more risk of heart failure as in year 2019, out of 135 non-ischemic cardiomyopathy patients 43% of people died.
By End-User
- Hospitals: The largest segment, hospitals and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with cardiac resynchronization therapy. Growing awareness and increasing efficiency of musculoskeletal system disorder treatment are projected to drive the growth of this segment during the forecast period.
- Cardiac Specialty Centers: A small segment, these centers provide immediate pain relief and rudimentary surgical care.
- Academic and Research Organizations: This segment includes home care and senior citizen centers.
By Region
- Americas: The largest regional cardiac resynchronization therapy market, the prevalence of cardiac resynchronization therapy is high in the Americas; the region also has a well-established healthcare industry.
- Europe: An increasing geriatric population is leading to a rise in the number of musculoskeletal system disorder cases.
- Asia-Pacific: The fastest-growing regional cardiac resynchronization therapy market, Asia-Pacific is seeing a surge in the number of people afflicted with cardiac resynchronization therapy due to bad posture brought on by lifestyle changes, aging, and genetic predisposition.
- Middle East & Africa: The smallest market due to limited healthcare infrastructure and a very young population.
Cardiac Resynchronization Therapy (CRT) Market Key Players
- Medtronic
- Abbott
- BIOTRONIK, Inc.
- Boston Scientific Corporation
- Lepu Medical Technology Co., Ltd.
- Medico S.p.A.
- MicroPort Scientific Corporation
- Shree Pacetronix Ltd
- Others
Report Scope:
Report Attribute/Metric
|
Details
|
Market Size
|
USD 4.09 Billion 2030
|
CAGR
|
4.10% 2030
|
Base Year
|
2021
|
Forecast Period
|
2022-2030
|
Historical Data
|
2020
|
Forecast Units
|
Value (USD Billion)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Segments Covered
|
Application, Type, End-User and Region
|
Geographies Covered
|
Americas, Europe, Asia-Pacific, Middle East & Africa
|
Key Vendors
|
Medtronic, Abbott, BIOTRONIK, Inc., Boston Scientific Corporation, Lepu Medical Technology Co., Ltd., Medico S.p.A., MicroPort Scientific Corporation, Shree Pacetronix Ltd and Others
|
Key Market Opportunities
|
Increasing awareness of cardiac resynchronization therapy (CRT) devices and favorable government regulation towards reimbursement scenario
|
Key Market Drivers
|
· Increasing sedentary lifestyle
Rising geriatric population
Rising investments in the healthcare
Increasing technologically advances in medical devices
The rising number of surgical procedures
The growing number of intensive care units
|
Frequently Asked Questions (FAQ) :
The global cardiac resynchronization therapy (CRT) market is projected to reach a valuation of USD 4.09 Billion by 2030.
The global cardiac resynchronization therapy (CRT) market is projected to grow at approximately 4.10% CAGR during forecast period (2022-2030).
Increasing technologically advances in medical devices.
North America holds the largest share in the global cardiac resynchronization therapy (CRT) market, followed by Europe and the Asia Pacific, respectively.
Abbott, Medtronic, BIOTRONIK, Inc., Lepu Medical Technology Co., Ltd., Boston Scientific Corporation, Medico S.p.A., Shree Pacetronix Ltd., and MicroPort Scientific Corporation, are some of the major players operating in the Cardiac resynchronization therapy (CRT) market.
Key Questions Answered
- ✅Global Market Outlook
- ✅In-depth analysis of global and regional trends
- ✅Analyze and identify the major players in the market, their market share, key developments, etc.
- ✅To understand the capability of the major players based on products offered, financials, and strategies.
- ✅Identify disrupting products, companies, and trends.
- ✅To identify opportunities in the market.
- ✅Analyze the key challenges in the market.
- ✅Analyze the regional penetration of players, products, and services in the market.
- ✅Comparison of major players’ financial performance.
- ✅Evaluate strategies adopted by major players.
- ✅Recommendations
Request Free Sample
Why Choose Market Research Future?
- ✅Vigorous research methodologies for specific market.
- ✅Knowledge partners across the globe
- ✅Large network of partner consultants.
- ✅Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- ✅Trusted by fortune 500 companies/startups/universities/organizations
- ✅Large database of 5000+ markets reports.
- ✅Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report